On April 25, 2026, EG BioMed proudly renewed its support as both a sponsor and an active participant in PurpleStride 2026, the nationwide walk organized by the Pancreatic Cancer Action Network (PanCAN). Walking alongside survivors, families, healthcare professionals, and researchers, our team stood united in a shared mission: to elevate public awareness of pancreatic cancer and champion breakthroughs in early detection.
The collective funds raised through the PurpleStride movement are dedicated to PanCAN’s vital patient programs. This includes funding comprehensive support services, scaling molecular profiling and precision medicine initiatives, and accelerating research into early detection tools and transformative therapies.
Advancing ctDNA Technology A New Frontier in Early Detection
Pancreatic cancer remains exceptionally challenging to diagnose in its early stages due to its asymptomatic nature. To alter this clinical landscape, EG BioMed is harnessing the power of liquid biopsy. Our proprietary EG-Pancreatic Blood Test leverages circulating tumor DNA (ctDNA) technology to offer a non-invasive detection solution, delivering highly reliable and early risk assessments for high-risk individuals.
Backed by global patents and rigorous regulatory certifications, this advanced diagnostic tool is designed to facilitate earlier clinical interventions, giving patients a critical head start.
At this year’s PurpleStride event, the EG BioMed booth became a hub for community engagement. In addition to educating attendees on the impact of genomic detection, our team distributed custom purple teddy bear towels and informative brochures, blending our corporate identity with a heartfelt gesture of solidarity for the cause.
Moving forward, EG BioMed remains dedicated to pioneering innovations in cancer diagnostics and backing public health campaigns that bring measurable hope and clinical utility to patients and families worldwide.
Take Control of Your Health with Proactive Detection
To ensure greater clinical access across the United States, EG BioMed is continuously expanding its service channels. The pancreatic cancer blood testing service is available through dedicated clinic consultations as well as an independent online blood collection scheduling portal.
【 Online Blood Collection Service 】
To ensure the highest standard of care, all online bookings will first undergo an evaluation by a licensed physician. Upon clinical approval, your blood collection appointment will be formally scheduled and arranged.
Scheduling Portal： https://mdi.eg-bio.com/
【Partner Healthcare Provider】
For in-person clinical evaluations, medical consultations, or localized care, please reach out to our primary clinical partner：
Partner Clinic: Myrostar Health (Direct Primary Care)
Address: 1515 116th Ave N Ste 101, Bellevue, WA 98004
Phone: (206) 687-1558
Email: hello@myrostar.com
(Note：Detection consultations are also available through other designated providers, including Professional Medical Corporation.)
Disclaimer：The underlying technology for this pancreatic cancer blood test is exclusively licensed to YD Biopharma for commercial development, marketing, and distribution within the U.S. market. YD Biopharma is committed to delivering premium diagnostic services. If you have a family history or other risk factors associated with pancreatic cancer, please consult with the medical team at Myrostar Health to see if this screening is right for you.